These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 21138519)

  • 1. Phosphate-binding efficacy of crushed vs. chewed lanthanum carbonate in hemodialysis patients.
    How PP; Anattiwong P; Mason DL; Arruda JA; Lau AH
    Hemodial Int; 2011 Jan; 15(1):95-9. PubMed ID: 21138519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of chewed vs. crushed lanthanum on phosphorus binding in healthy volunteers.
    How PP; Mason DL; Arruda JA; Lau AH
    Clin Nephrol; 2010 May; 73(5):370-3. PubMed ID: 20420797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of oral powder compared with chewable tablets for lanthanum carbonate administration in hemodialysis patients.
    Sakurada T; Oishi D; Shibagaki Y; Yasuda T; Kimura K
    Hemodial Int; 2013 Oct; 17 Suppl 1():S2-6. PubMed ID: 24134326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Questionnaire survey and serum phosphorus levels in maintenance hemodialysis patients switching lanthanum carbonate formulation from chewable tablets to granules.
    Mukai I; Yoshizawa T; Kumagai J; Takahashi N; Tsuchiya S
    Ther Apher Dial; 2014 Jun; 18 Suppl 1():28-33. PubMed ID: 24953764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia.
    Joy MS; Finn WF;
    Am J Kidney Dis; 2003 Jul; 42(1):96-107. PubMed ID: 12830461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study.
    Mehrotra R; Martin KJ; Fishbane S; Sprague SM; Zeig S; Anger M;
    Clin J Am Soc Nephrol; 2008 Sep; 3(5):1437-45. PubMed ID: 18579668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Additional reduction in serum phosphorus levels by pulverized lanthanum carbonate chewable in hemodialysis patients.
    Yamashita T; Ogawa T; Takahashi M; Mitsuhashi T; Shizuku J; Takahashi N; Ohba T; Miyajima S; Kabaya T; Otsuka K; Nitta K
    Ther Apher Dial; 2013 Apr; 17 Suppl 1():54-9. PubMed ID: 23586514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion to lanthanum carbonate monotherapy effectively controls serum phosphorus with a reduced tablet burden: a multicenter open-label study.
    Vemuri N; Michelis MF; Matalon A
    BMC Nephrol; 2011 Sep; 12():49. PubMed ID: 21962172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis.
    Finn WF; Joy MS;
    Curr Med Res Opin; 2005 May; 21(5):657-64. PubMed ID: 15969865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of pharmacodynamic equivalence and tolerability of lanthanum carbonate oral powder and tablet formulations: a single-center, randomized, open-label, 2-period crossover study in healthy subjects.
    Pierce D; Hossack S; Robinson A; Zhang P; Martin P
    Clin Ther; 2012 Jun; 34(6):1290-1300.e2. PubMed ID: 22657252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is granular formulation of lanthanum carbonate more effective than chewable tablets?
    Okamoto H; Haruhara K; Kamejima S; Mafune H; Manabe M; Kanzaki G; Mashiko H; Yokoo T
    Ther Apher Dial; 2014 Jun; 18 Suppl 1():23-7. PubMed ID: 24953763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden.
    Hutchison AJ; Laville M;
    Nephrol Dial Transplant; 2008 Nov; 23(11):3677-84. PubMed ID: 18577536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative evaluation of the in vitro efficacy of lanthanum carbonate chewable tablets.
    Yang Y; Bykadi S; Carlin AS; Shah RB; Yu LX; Khan MA
    J Pharm Sci; 2013 Apr; 102(4):1370-81. PubMed ID: 23334989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study.
    Al-Baaj F; Speake M; Hutchison AJ
    Nephrol Dial Transplant; 2005 Apr; 20(4):775-82. PubMed ID: 15703206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients.
    Finn WF;
    Clin Nephrol; 2006 Mar; 65(3):191-202. PubMed ID: 16550750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of change in the formulation of lanthanum carbonate on laboratory parameters.
    Takita T; Furuhashi M; Fujimoto T; Suzuki H; Harada M; Maruyama S; Tamiya R; Kamiya E; Okamoto M; Tukada A; Furuhashi M; Kato A
    Ther Apher Dial; 2014 Jun; 18 Suppl 1():18-22. PubMed ID: 24953762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
    Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
    Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of continuous oral administration of lanthanum carbonate over 24 months.
    Ishizu T; Hong Z; Matsunaga T; Kaneko Y; Taru Y
    Ther Apher Dial; 2013 Apr; 17 Suppl 1():22-8. PubMed ID: 23586509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognitive function in Stage 5 chronic kidney disease patients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy.
    Altmann P; Barnett ME; Finn WF;
    Kidney Int; 2007 Feb; 71(3):252-9. PubMed ID: 17035945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.